2021-2022 PDMP Annual Report

Prescription Drug Monitoring Program Annual Report | 2021-22 3 Message from the State Surgeon General As Florida's State Surgeon General, it gives me great pleasure to present the Division of Medical Quality Assurance (MQA), Prescription Drug Monitoring Program's (PDMP) 2021- 22 Annual Report. The PDMP, better known as Electronic-Florida Online Reporting of Controlled Substance Evaluation Program (E- FORCSE®), report contains information on the program's operation and system metrics, vital operational activities, and findings from various program evaluation activities. This year, through expanded outreach and education, we have seen an increase in prescriber and dispenser registration by 12.2 percent, from 147,331 to 165,281. The increase in enrollment led to a rise in the number of queries by 18.5 percent, from 120.5 million to 121.2 million. The PDMP is progressing in connecting users and expanding access through its integration with electronic health records and pharmacy dispensing systems. The PDMP has approved 2,265 integrations across the state, allowing prescribers and dispensers to access PDMP information within the existing workflows. According to the most recent data, 6,342 dispensers reported over 30 million controlled substance prescriptions to the database. There are 17,491,848 residents 18 years of age and older in Florida, of which 28.9 percent have been dispensed a controlled substance. For the seventh consecutive year, oxycodone sustained action (SA), alprazolam, and hydrocodone SA were the three most dispensed controlled substances, representing 35.6 percent of the total controlled substances dispensed during 2021-22. In addition to managing the daily operations of the PDMP and its tens of thousands of users, I am proud of the PDMP for developing a cutting-edge data warehouse to communicate key performance indicators and program metrics augmented by machine learning and data science. It is exciting to see Florida on the forefront of this new capability by empowering advanced analytics to develop predictive models to improve surveillance policies, techniques, and risk mitigation. The following pages describe the trends identified in Florida’s Prescription Drug Monitoring System (PDMS). I hope this report provides a better understanding of the PDMP’s role in protecting, promoting, and improving the health of all people in Florida. Joseph A. Ladapo, MD, PhD State Surgeon General